Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week.
Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.
Google Ventures and US healthcare specialist Redmile were among a group of investors supporting a £35.5 million funding round for UK biotech Evox Therapeutics, which specialises in drugs de
Boehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosi
Boehringer Ingelheim has revealed further details about its plans for a new kind of cancer immunotherapy licensed in from biotech OSE Therapeutics at the beginning of last month, saying it
Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.